9051 Mira Mesa Blvd, #910094
San Diego, CA 92191
Tel: 760-390-3989

H1N1 New Caledonia

H1N1 Influenza-A Virus New Caledonia/20/99 IVR 116
VAG0155

Product Overview

Name	H1N1 New Caledonia

Description

H1N1 Influenza-A Virus New Caledonia/20/99 IVR 116

Introduction

H1N1 is a subtype specie of Influenza A virus. H1N1 Influenza Virus has mutated into various strains such as the Spanish Flustrain, mild humanflu strains, endemic pigstrains, and various strains found in birds. The Influenza A Virus is a globular particle about 100nm in diameter, sheathed in a lipid bilayer derived from the plasma membrane of its host. Studded in the lipid bilayer are two integral membrane proteins some 500 molecules of hemagglutinin ("H") and some 100 molecules of neuraminidase ("N"). Within the lipid bilayer are 3000 molecules of matrix protein and 8 pieces of RNA. Each of the 8 RNA molecules is associated with many copies of a nucleoprotein, several molecules of the three subunits of its RNA polymerase some "non-structural" protein molecules of uncertain function.

Physical Appearance

Sterile Filtered colorless solution.

Formulation

The H1N1 A/New Caledonia/20/99 IVR solution contains STE, 0.09% sodium azide (NaN 3) and 0.005% thimerosal.

Stability

A/New Caledonia/20/99 IVR although stable 4°C for 4 weeks, should be stored below -18°C. Please prevent freeze-thaw cycles.

Purity

Greater than 90.0% as determined by ELISA analysis.

References

1. Title: A Patented Strain of Bacillus coagulans Increased Immune Response to Viral Challenge . Publication : DOI : 10.3810/pgm.2009.03.1971 Postgraduate Medicine: Volume: 121 No.2 Link : H1N1 New Caledonia prospec publication 2. Title: Clonal dissection of the human memory B-cell repertoirefollowing infection and vaccination Publication: European journal of immunology 39.5 (2009): 1260-1270. Link: H1N1 Influenza-A Virus prospec publication

Inactivation

Thimerosal and beta propiolactone treatment This product has been treated in a manner consistent with methods of

inactivation. Generally accepted good laboratory practices appropriate to microbiological/viral safe handling practices and techniques are required at work.

Immunological Activity

Tested with anti-influenza A monoclonal antibodies in ELISA.Serological studies of influenza A virus, immunogen for antibody production.

Precautions

H1N1 New Caledonia is for research use only and not for use in diagnostic or therapeutic procedures.